Business Description
Genovate Biotechnology Co Ltd
NAICS : 325412
SIC : 2834
ISIN : TW0004130000
Description
Genovate Biotechnology Co Ltd develops, produces, manufactures, and markets pharmaceutical preparations, drug substances, and intermediates. The company is also engaged in sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 189.03 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-EBITDA | 0.05 | |||||
| Interest Coverage | 42.54 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 10.96 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.3 | |||||
| 3-Year EBITDA Growth Rate | -4.3 | |||||
| 3-Year EPS without NRI Growth Rate | -9.1 | |||||
| 3-Year FCF Growth Rate | -5.4 | |||||
| 3-Year Book Growth Rate | 0.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.81 | |||||
| 9-Day RSI | 46.68 | |||||
| 14-Day RSI | 41.75 | |||||
| 6-1 Month Momentum % | -8.7 | |||||
| 12-1 Month Momentum % | -16.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.93 | |||||
| Quick Ratio | 4.88 | |||||
| Cash Ratio | 4.06 | |||||
| Days Inventory | 158.51 | |||||
| Days Sales Outstanding | 62.63 | |||||
| Days Payable | 42.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.72 | |||||
| Dividend Payout Ratio | 1.1 | |||||
| 3-Year Dividend Growth Rate | -26.8 | |||||
| Forward Dividend Yield % | 0.72 | |||||
| 5-Year Yield-on-Cost % | 0.28 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | 0.71 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.45 | |||||
| Operating Margin % | 2.97 | |||||
| Net Margin % | 3.1 | |||||
| FCF Margin % | 7.3 | |||||
| ROE % | 1.07 | |||||
| ROA % | 0.98 | |||||
| ROIC % | 1.16 | |||||
| ROC (Joel Greenblatt) % | 4.31 | |||||
| ROCE % | 1.43 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 155.51 | |||||
| PE Ratio without NRI | 155.51 | |||||
| Shiller PE Ratio | 44.47 | |||||
| Price-to-Owner-Earnings | 62.46 | |||||
| PS Ratio | 4.7 | |||||
| PB Ratio | 1.59 | |||||
| Price-to-Tangible-Book | 1.6 | |||||
| Price-to-Free-Cash-Flow | 65.69 | |||||
| Price-to-Operating-Cash-Flow | 36.98 | |||||
| EV-to-EBIT | 86 | |||||
| EV-to-EBITDA | 31.23 | |||||
| EV-to-Revenue | 3.59 | |||||
| EV-to-FCF | 47.74 | |||||
| Price-to-Projected-FCF | 1.76 | |||||
| Price-to-Median-PS-Value | 0.71 | |||||
| Price-to-Graham-Number | 3.33 | |||||
| Price-to-Net-Current-Asset-Value | 3.75 | |||||
| Price-to-Net-Cash | 6.1 | |||||
| Earnings Yield (Greenblatt) % | 1.17 | |||||
| FCF Yield % | 1.6 | |||||
| Forward Rate of Return (Yacktman) % | -3.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genovate Biotechnology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 512.082 | ||
| EPS (TTM) (NT$) | 0.136 | ||
| Beta | 0.1 | ||
| Volatility % | 14.65 | ||
| 14-Day RSI | 41.75 | ||
| 14-Day ATR (NT$) | 0.242458 | ||
| 20-Day SMA (NT$) | 21.4125 | ||
| 12-1 Month Momentum % | -16.02 | ||
| 52-Week Range (NT$) | 20.388349 - 26.310679 | ||
| Shares Outstanding (Mil) | 111.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genovate Biotechnology Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genovate Biotechnology Co Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genovate Biotechnology Co Ltd Frequently Asked Questions
What is Genovate Biotechnology Co Ltd(ROCO:4130)'s stock price today?
The current price of ROCO:4130 is NT$21.15. The 52 week high of ROCO:4130 is NT$26.31 and 52 week low is NT$20.39.
When is next earnings date of Genovate Biotechnology Co Ltd(ROCO:4130)?
The next earnings date of Genovate Biotechnology Co Ltd(ROCO:4130) is .
Does Genovate Biotechnology Co Ltd(ROCO:4130) pay dividends? If so, how much?
The Dividend Yield %  of Genovate Biotechnology Co Ltd(ROCO:4130) is 0.72% (As of Today), Highest Dividend Payout Ratio of Genovate Biotechnology Co Ltd(ROCO:4130) was 132.67. The lowest was 0.24. And the median was 1.09. The  Forward Dividend Yield % of Genovate Biotechnology Co Ltd(ROCO:4130) is 0.72%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers